Nuvectra (NVTR) 10-K 6 Mar 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Feb. 21, 2018	Jun. 30, 2017
Document Information [Line Items]
Entity Registrant Name	Nuvectra Corp
Entity Central Index Key	1,648,893
Trading Symbol	nvtr
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		14,109,967
Entity Public Float			$ 134.2
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 30, 2016
Current assets:
Cash and cash equivalents	$ 28,165	$ 63,710
Trade accounts receivable, net of allowance for doubtful accounts of $417 in fiscal 2017 and $10 in fiscal 2016	10,875	3,177
Inventories	4,978	5,233
Prepaid expenses and other current assets	1,011	443
Total current assets	45,029	72,563
Property, plant and equipment, net	6,219	6,317
Intangible assets, net	1,428	1,714
Goodwill	38,182	38,182
Other long-term assets	245	526
Total assets	91,103	119,302
Current liabilities:
Accounts payable	2,043	9,928
Accrued liabilities	8,827	3,355
Accrued compensation	4,392	2,757
Short-term debt	789
Total current liabilities	16,051	16,040
Other long-term liabilities	993	940
Long-term debt, net	25,886	13,744
Total liabilities	42,930	30,724
Commitments and contingencies (Note 9)
Stockholders’ equity:
Common stock, $0.001 par value, 100,000,000 shares authorized; 10,849,385 and 10,319,627 shares issued and outstanding in fiscal 2017 and fiscal 2016, respectively	11	10
Additional paid-in capital	125,999	121,806
Accumulated other comprehensive loss	(1)	(2)
Accumulated deficit	(77,836)	(33,236)
Total stockholders’ equity	48,173	88,578
Total liabilities and stockholders’ equity	$ 91,103	$ 119,302

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 30, 2016
Trade accounts receivable, allowance for doubtful accounts	$ 417	$ 10
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	10,849,385	10,319,627
Common stock, shares outstanding (in shares)	10,849,385	10,319,627

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016
Sales:
Product	$ 30,323	$ 9,314
Service	1,513	3,221
Total sales	31,836	12,535
Cost of sales:
Product	14,989	4,806
Service	897	1,624
Total cost of sales	15,886	6,430
Gross profit	15,950	6,105
Operating expenses:
Selling, general and administrative expenses	43,860	28,507
Research, development and engineering costs, net	14,102	14,524
Other operating expenses		476
Total operating expenses	57,962	43,507
Operating loss	(42,012)	(37,402)
Interest expense, net	1,959	1,311
Other expense (income), net	604	(285)
Loss before provision for income taxes	(44,575)	(38,428)
Provision for income taxes	25
Net loss	(44,600)	(38,428)
Other comprehensive loss:
Unrealized holding gain (loss) on investments arising during period	1	(2)
Other comprehensive loss	1	(2)
Comprehensive loss	$ (44,599)	$ (38,430)
Basic and diluted net loss per share (in dollars per share)	$ (4.22)	$ (3.74)
Basic and diluted weighted average shares outstanding (in shares)	10,576	10,277

Consolidated Cash Flow Statemen

Consolidated Cash Flow Statements - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016
Cash flows from operating activities:
Net loss	$ (44,600)	$ (38,428)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for uncollectible accounts	407
Writedowns of excess and obsolete inventories	417	156
Depreciation and amortization	1,615	2,243
Debt related amortization included in interest expense	759	510
Stock-based compensation	2,315	2,370
Loss on disposal of property, plant and equipment		226
Changes in operating assets and liabilities:
Trade accounts receivable	(8,105)	(2,760)
Inventories	(162)	(5,365)
Prepaid expenses and other current assets	(568)	(322)
Accounts payable and other current liabilities	(2,412)	12,610
Accrued compensation	1,635	2,035
Other long-term liabilities	502	940
Net cash used in operating activities	(48,197)	(25,785)
Cash flows from investing activities:
Acquisition of property, plant and equipment	(1,231)	(4,031)
Net cash used in investing activities	(1,231)	(4,031)
Cash flows from financing activities:
Borrowings under credit facility	12,500	15,000
Purchase of non-controlling interests		(6,818)
Net funding and capital contribution provided by Integer		86,421
Proceeds from the exercise of stock options and warrants	1,430	249
Payment of debt issuance costs	(47)	(1,528)
Net cash provided by financing activities	13,883	93,324
Net (decrease) increase in cash and cash equivalents	(35,545)	63,508
Cash and cash equivalents, beginning of period	63,710	202
Cash and cash equivalents, end of period	28,165	63,710
Supplemental Disclosure of Cash Flow Information:
Interest paid	1,427	822
Income taxes paid	13
Acquisition of property, plant and equipment accrued not paid		$ 129

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Parent [Member]	Total
Balance (in shares) at Jan. 01, 2016
Balance at Jan. 01, 2016			$ (125,094)		$ 162,934	$ 37,840
Issuance of common stock (in shares)	10,258,000
Issuance of common stock	$ 10	119,624	125,094		(244,728)
Issuance of common stock warrants		238				$ 238
Option exercises (in shares)	51,000					50,794
Option exercises		249				$ 249
Restricted stock issued, net of stock forfeited (in shares)	11,000
Stock-based compensation		1,695			675	2,370
Capital contribution from Integer					75,000	75,000
Net funding provided by Integer					11,311	11,311
Unrealized holding period gain (loss)				(2)		(2)
Net loss			(33,236)		(5,192)	(38,428)
Balance (in shares) at Dec. 30, 2016	10,320,000
Balance at Dec. 30, 2016	$ 10	121,806	(33,236)	(2)		88,578
Issuance of common stock warrants		449				$ 449
Option exercises (in shares)						261,748
Restricted stock issued, net of stock forfeited (in shares)	236,000
Stock-based compensation		2,315				$ 2,315
Unrealized holding period gain (loss)				1		1
Net loss			(44,600)			(44,600)
Option and warrant exercises (in shares)	293,000
Option and warrant exercises	$ 1	1,429				1,430
Balance (in shares) at Dec. 31, 2017	10,849,000
Balance at Dec. 31, 2017	$ 11	$ 125,999	$ (77,836)	$ (1)		$ 48,173

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations – Nuvectra Corporation, together with its wholly-owned subsidiaries (i) Algostim, LLC (“Algostim”), (ii) PelviStim LLC (“PelviStim”), and (iii) NeuroNexus Technologies, Inc. (“NeuroNexus”) (collectively “Nuvectra” or the “Company”), is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (“SCS”) System (“Algovita”) is the Company’s first Basis of Presentation – The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions to Form 10 X. On March 14, 2016 Integer”), completed the spin-off of the Company, at which time the Company became a separate public company (the “Spin-off”). Prior to the Spin-off, the Company was a limited liability company named QiG Group, LLC (“QiG”). Prior to March 14, 2016, 2016 Prior to March 14, 2016, ons, including executive oversight, finance, legal, human resources, tax, information technology, product development, corporate procurement, and facilities. These expenses were charged to the Company on the basis of direct usage, when identifiable, with the remainder allocated primarily on a pro rata basis of estimated hours incurred, headcount, square footage, or other measures. The Company’s management considers the expense allocation methodology and results to be reasonable for all periods presented. However, these allocations are not 14 5 Liquidity and Capital Resources – The Company has incurred significant net losses and negative cash flows from operations since inception and expects to incur additional net losses for the foreseeable future. Immediately prior to completion of the Spin-off, Integer made a cash capital contribution to Nuvectra of $75 $23.8 3,248,750 February 2018, $5 six twelve no may may not may may no Fiscal Year End – Beginning in fiscal year 2017, 2017, fifty fifty-three December 31. 2016 December 30, 2016 fifty-two Use of Estimates – The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of sales and expenses during the reporting period. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include inventories, tangible and intangible asset valuations, revenue, stock-based compensation, and income tax accounts. Fair Value Measurements – Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e . three Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 1 not Level 2 – Valuation is determined from quoted prices for similar assets or liabilities in active markets, quoted prices for identical instruments in markets that are not Level 3 – Valuation is based on unobservable inputs that are significant to the overall fair value measurement. The degree of judgment in determining fair value is greatest for Level 3 The availability of observable inputs can vary and is affected by a wide variety of factors, including, the type of asset/liability, whether the asset/liability is established in the marketplace, and other characteristics particular to the valuation. To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may Fair value is a market-based measure considered from the persp ective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not 11 Cash and Cash Equivalents – Cash and Cash Equivalents consist of cash and highly liquid, short-term investments with maturities at the time of purchase of three Concentration of Credit Risk – Financial instruments that potentially subject the Company to concentration of credit risk consist principally of trade accounts receivable owed to the Company by its customers. The Company performs on-going credit evaluations of its customers. During fiscal year 2016, $3.1 25% No 10% 2016, no 10% 2017. December 30, 2016 $0.3 No 10% December 30, 2016, no 10% December 31, 2017. may 13 Allowance for Doubtful Accounts – The Company provides credit, in the normal course of business, to its customers in the form of trade accounts receivable. Credit is extended based on evaluation of a customer’s financial condition and collateral is not not $0.4 $0.01 2017 2016, Inventories – The value of inventories, comprised solely of finished goods, are stated at the lesser of net realizable value or cost, determined using the first first not $0.4 $0.2 2017 2016, may Property, Plant and Equipment, Net (“ PP&E”) – PP&E is carried at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the assets, as follows: buildings and building improvements 7 40 3 8 3 10 The Company is a party to various operating lease agreements for buildings, machinery, and equipment. Lease expense includes the effect of escalation clauses , which are accounted for ratably over the lease term. Note 2 Amortizing Intangible Assets, Net – Amortizing Intangible Assets, Net consists primarily of purchased technology and patents, and customer lists. The Company amortizes its definite-lived intangible assets over their estimated useful lives utilizing an accelerated method of amortization, which approximates the projected cash flows used to fair value those intangible assets at the time of acquisition. The amortization period for the Company’s amortizing intangible assets are as follows: purchased technology and patents 6 7 3 Impairment of Long-Lived Assets – The Company assesses the impairment of definite-lived long-lived assets or asset groups when events or changes in circumstances indicate that the carrying value may not not, not 50 Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. The projected cash flows for eac h asset or asset group considers multiple factors, including current revenue from existing customers, proceeds from the sale of the asset or asset group and expected profit margins giving consideration to historical and expected margins. If the carrying value is not no Goodwill Valuation – The Company assesses its goodwill balances for impairment on the last day of each fiscal year, or more frequently if certain indicators are present or changes in circumstances, as described above, suggest that impairment may first not December 31, 2017 December 30, 2016 not . The following represents our goodwill balance by reportable segment. Changes to goodwill during the years ended December 31, 2017 December 30, 2016 Nuvectra NeuroNexus Total Balance – January 1, 2016 Goodwill, gross $ 33,491 $ 4,691 $ 38,182 Accumulated impairment losses — — — Goodwill, net 33,491 4,691 38,182 Goodwill impairment charge — — — Balance – December 30, 2016 Goodwill, gross 33,491 4,691 38,182 Accumulated impairment losses — — — Goodwill, net 33,491 4,691 38,182 Goodwill impairment charge — — — Balance – December 31, 2017 Goodwill, gross 33,491 4,691 38,182 Accumulated impairment losses — — — Goodwill, net $ 33,491 $ 4,691 $ 38,182 Warranty Reserve – The Company offers a warranty on certain of its products and has established a warranty reserve, as a component of other current liabilities, for any potential claims. The Company estimates its warranty reserve based upon an analysis of all identified or expected claims and an estimate of the cost to resolve those claims. Factors that affect the Company’s warranty liability include the number of units sold, historical and anticipated rates of warranty claims, and differences between actual and expected warranty costs per claim. The Company periodically assesses the adequacy of its warranty liabilities and adjusts the amounts as necessary. Revenue Recognition – The Company recognizes revenue when it is realized or realizable and earned. This occurs when persuasive evidence of an arrangement exists, delivery has occurred, the risk of loss is transferred, the price is fixed or determinable, the buyer is obligated to pay (i.e., not no Service revenue is recognized as the services are performed. The Company’s development services are typically provided on a fixed-fee basis. The revenues for such longer duration projects are typically recognized using the proportional performance method. In using the proportional performance method, revenues are generally recorded based on the percentage of effort incurred to date on a contract relative to the estimated total expected contract effort. Estimating total contract effort and progress to completion on the arrangements, as well as whether a loss is expected to be incurred on the contract, requires significant judgment. Management uses historical experience, project plans and an assessment of the risks and uncertainties inherent in the arrangements to establish these estimates. Various uncertainties may may not not Research, Development and Engineering Costs, Net (“ RD&E”) – RD&E costs are expensed as incurred. The primary costs are salary and employee benefits for our specialists in software engineering, mechanical engineering, electrical engineering, and graphical user interface design, design verification testing expenses, which include salary and employee benefits for our engineers who test the design and materials used in our medical devices, salary, benefits and other personnel-related expenses for our regulatory, quality and clinical affairs employees, material costs used in development projects and subcontracting costs. Any reimbursements received from government grants are recorded as a reduction of the research, development and engineering costs incurred. Stock-Based Compensation – three not. The Black-Scholes option-pricing model was used to estimate the fair value of stock options granted. For service-based and nonmarket-base d performance restricted stock unit awards, the fair market value of the award is determined based upon the closing value of the stock price on the grant date. Historically, for market-based performance restricted stock unit awards, the fair market value of the award was determined utilizing a Monte Carlo simulation model, which projected the value of Integer’s stock under numerous scenarios and determined the value of the award based upon the present value of those projected outcomes. The total expense r ecognized over the vesting period will only be for those awards that ultimately vest, excluding market and nonmarket performance award considerations. Note 5 Insurance – The Company historically participated in Integer’s various insurance programs, to insure for property and casualty risks, product liability, employee health care, workers’ compensation and other casualty losses. Many of the potential losses were covered by Integer under conventional insurance programs with third March 14, 2016 no 14 Interest Expense, Net – Interest expense, including amortization of deferred financing fees and discounts on debt, related to the Company’s Credit Facility was $2.3 $1.4 2017 2016, $0.3 $0.1 2017 2016, Comprehensive Loss – The Company’s comprehensive loss as reported in the Consolidated Statements of Operations and Comprehensive Loss is comprised of the Company’s net loss and unrealized holding period gains and / or losses related to investments. Income Taxes – The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not The Company records uncertain tax positions in a ccordance with ASC 740 two 1 not 2 not 50 The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying Consolidated Statement of Operations. Subsequent Events – The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. On February 5, 2018, public offering of 3,248,750 $8.00 423,750 $26.0 See Note 7 Debt” for additional information on the Company’s credit facility as amended in February 2018.

Note 2 - Property, Plant and Eq

Note 2 - Property, Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	2. PROPERTY, PLANT AND EQUIPME NT, NET PP&E, net is comprised of the following (in thousands): At December 31, 2017 December 30, 2016 Machinery and equipment $ 2,329 $ 1,675 Buildings and building improvements 2,855 2,854 Information technology hardware and software 4,431 3,191 Furniture and fixtures 374 314 Land and land improvements 390 390 Construction work in process 342 1,066 Total, gross 10,721 9,490 Accumulated depreciation (4,502 ) (3,173 ) Total, net $ 6,219 $ 6,317 Depreciation and rent expense for PP&E were as follows (in thousands): Year Ended December 31, 2017 December 30, 2016 Depreciation expense $ 1,329 $ 1,974 Rent expense 520 519 Minimum future estimated annual operating lease payments as of December 31, 2017 2018 $ 445 2019 401 2020 408 2021 415 2022 282 Thereafter — Total estimated operating lease payments $ 1,951

Note 3 - Intangible Assets, Net

Note 3 - Intangible Assets, Net	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	3. INTANGIBLE ASSETS, NET Inta ngible assets, net are comprised of the following (in thousands): Gross Carrying Amount Accumulated Amortization Net Carrying Amount At December 30, 2016 Technology and patents $ 1,058 $ (498 ) $ 560 Customer lists 1,869 (715 ) 1,154 Total intangible assets $ 2,927 $ (1,213 ) $ 1,714 At December 31, 2017 Technology and patents $ 1,058 $ (624 ) $ 434 Customer lists 1,869 (875 ) 994 Total intangible assets $ 2,927 $ (1,499 ) $ 1,428 Aggregate intangible asset amortization expense is classified as follows (in thousands): Year Ended December 31, 2017 December 30, 2016 Cost of sales $ 126 $ 110 Selling, general and administrative expenses 160 159 Total intangible asset amortization expense $ 286 $ 269 Estimated future intangible asset amortization expense based on the current carrying value is as follows for the years ending December 31 ( Estimated Amortization Expense 2018 $ 298 2019 293 2020 209 2021 194 2022 108 Thereafter 326 Total estimated amortization expense $ 1,428

Note 4 - Accrued Liabilities

Note 4 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. Accrued Liabilities Accrued liabilities consisted of the following (in thousands): At December 31, 2017 December 30, 2016 Inventory purchases $ 5,825 $ 547 Regulatory, clinical and quality 358 640 Legal 358 98 Deferred revenue 335 — Sales and marketing 321 108 Operations engagement fee 200 600 Interest 199 99 Warranty reserve 195 98 Research and development 164 165 Sales and use tax 145 56 Insurance 127 — Information technology system implementations 114 327 Travel and entertainment — 285 Accrued other 486 332 Total accrued liabilities $ 8,827 $ 3,355

Note 5 - Employee Benefit Plans

Note 5 - Employee Benefit Plans	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	5. EMPLOYEE BENEFIT PLANS Nuvectra Corporation 2016 – The Nuvectra Corporation 2016 “2016 March 14, 2016. 2016 may may 2016 2016 1,541,195. During fiscal year 2017, 548,057 2016 s and key employees. Compensation cost related to the 2016 2017 $2.3 During fiscal year 2016, 805,222 2016 s and key employees. Compensation cost related to the 2016 2016 $1.3 Stock-Based Compensation – Certain of the Company’s employees participated in the stock-based compensation programs of Integer and prior to the Spin-off received awards of time-based stock options and time- and performance-based restricted stock units, which typically vest over a three $0.2 $1.1 2017 2016, December 31, 2017, $3.3 1.6 . The components and classificatio n of stock-based compensation expense were as follows (in thousands): Year Ended December 31, 2017 December 30, 2016 Stock options $ 864 $ 638 Restricted stock and restricted stock units 1,451 1,732 Total stock-based compensation expense $ 2,315 $ 2,370 Year Ended December 31, 2017 December 30, 2016 Selling, general and administrative expense $ 1,992 $ 1,565 Research, development and engineering costs, net 323 336 Other operating expenses — 469 Total stock-based compensation expense $ 2,315 $ 2,370 The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model with weighted-average assumptions based on the grant date. The weighted average fair value and assumptions used to value options granted under the 2016 Year Ended December 31, 2017 December 30, 2016 Weighted average fair value $ 3.64 $ 4.52 Risk-free interest rate 2.06 % 1.72 % Expected volatility 55 % 55 % Holding period (in years) 6 10 Expected dividend yield — % — % The following table summarizes the stock option activity during fiscal year 2017: Number of Time-Vested Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding at December 30, 2016 873,992 $ 6.49 Granted 338,839 6.84 Exercised (261,748 ) 5.80 Forfeited or expired (80,263 ) 7.18 Outstanding at December 31, 2017 870,820 $ 6.78 7.59 $ 1,203,654 Exercisable at December 31, 2017 423,547 $ 6.53 6.18 $ 736,883 The Company received proceeds totaling $1. 4 261,748 32,425 2017. $0.2 50,794 2016. The following table summarizes the re stricted stock and restricted stock unit activity during fiscal year 2017: Time-Vested Activity Weighted Average Fair Value Nonvested at December 30, 2016 551,224 $ 6.90 Granted 209,218 6.76 Vested (229,667 ) 8.76 Forfeited (101,770 ) 6.52 Nonvested at December 31, 2017 429,005 $ 6.88 Nuvectra Bonus Plan – The terms of the Nuvectra Corporation Bonus Plan (the “Bonus Plan”) provide for both annual discretionary defined contribution cash bonuses and performance-based bonuses based upon Nuvectra’s company-wide performance measures and, for certain employees, individual performance measures that are set by Nuvectra’s executive management and, in some instances, members of the Board of Directors. Compensation cost related to the Bonus Plan for fiscal year 2017 2016 $1.9 $1.0 Defined Contribution Plans – The Company sponsors a defined contribution 401 401 1986, 401 2017 2016 25% 6% $0.3 $0.2 2017 2016, Integer sponsors a defined contribution 401 ’s employees historically participated. The plan provides for the deferral of employee compensation under Section 401 first 2016 35% 6% 401 first 2016 $0.2 2016.

Note 6 - Other Operating Expens

Note 6 - Other Operating Expenses	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Other Operating Income and Expense [Text Block]	6. OTHER OPERATING EXPENSES Performance Restricted Stock Expense – As a result of the Spin-off, certain 2015 no $469,000 March 14, 2016 Asset Disposals – During fiscal year 2016, no 2017.

Note 7 - Debt

Note 7 - Debt	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	7. DEBT Long-term debt is comprised of the following (in thousands): At December 31, 2017 December 30, 2016 Term loan $ 29,631 $ 16,163 Deferred financing fees (962 ) (1,262 ) Discount on debt (1,994 ) (1,157 ) Total debt 26,675 13,744 Less current portion of long-term debt 789 — Total long-term debt $ 25,886 $ 13,744 Credit Facility – The Company has a credit facility, as amended in February 2018 ( $45,000,000 $27,500,000 February 2018 $12,500,000 February 2018, $5,000,000 six $25 March 31, 2019 sixty no may The Term Loans bear interest at a floating rate equal to the prime rate plus 4.15%, 8.65%. December 31, 201 7 8.40%. March 2020 30 September 1, 2022, 7.75% On March 18, 2016 $1,125,000 Piper Jaffray”), which equaled 2.50% $40 $5 $200,000 one $25,000 one one February 14, 2017, $25,000 February 2018, second $0.8 5% 3% first 2% second 1% The Loans are secured by a first f the assets of the Company, including, without limitation, all cash, deposit accounts, accounts receivable, equipment, inventory, contract rights, and the Company’s real property located in Blaine, Minnesota, but excluding all intellectual property of the Company (other than accounts receivable and proceeds of intellectual property). The Company’s intellectual property is subject to a negative pledge. The Company must maintain its primary operating and investment accounts with Silicon Valley Bank, which accounts are subject to customary control agreements. The Credit Facility contains customary representations and warranties, reporting and other covenants for credit facilities of this kind including prohibitions on the payment of cash dividends on the Co mpany’s capital stock and restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates. The Company is subject to a quarterly financial covenant requiring the Company to achieve specified minimum consolidated product revenues. As of December 31, 2017, On February 16, 2018, ent ( $27.5 $12.5 March 18, 2016, ( 56,533 $5.97 March 18, 2026, 56,533 $5.97 March 18, 2026. $0.2 As a condition to the lenders ’ funding the loans under the Credit Facility, concurrently with the funding under the initial term loan B commitment on September 28, 2017, ( 22,844 $12.31 September 28, 2027, 22,844 $12.31 September 28, 2027. $0.4 As a condition to the lenders ’ funding the loans under the Credit Facility, concurrently with the funding under the Term Loan B Commitment in February 2018, ( 30,245 $9.30 February 18, 2028, 30,245 $9.30 February 18, 2028. first 2018, Upon the funding of the term loan C commitment, Oxford Finance LLC and Silicon Valley Bank were each entitled to additional warrants for the purchase of Nuvectra common stock. The number of shares under each warrant were to be equal to the amount of the term loan made by each lender multiplied by 4.50% December 31, 2017 $0.4 not 11 Upon the funding of the Term Loan C Commitment, Oxford Finance LLC and Silicon Valley Bank will each be entitled to additional warrants for the purchase of Nuvectra common stock. The number of shares under each warrant will be equal to the amount of the Term Loan made by each lender multiplied by 4.50% Deferred Financing Fees – The change in deferred financing fees is as follows (in thousands): At January 1, 2016 $ — Additions during the period 1,528 Amortization during the period (266 ) At December 30, 2016 $ 1,262 At December 30, 2016 $ 1,262 Additions during the period 47 Amortization during the period (347 ) At December 31, 2017 $ 962 In accordance with Financial Accounting Standards Board (“ FASB”) Accounting Standards Update (“ASU”) 2015 03, 835 30

Note 8 - Income Taxes

Note 8 - Income Taxes	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	8. INCOME TAXES The provision for income taxes associated with the Company was comprised of the following (in thousands): Year Ended December 31, 2017 December 30, 2016 Current tax expense $ 25 $ — Deferred tax benefit (2,743 ) (13,997 ) Change in valuation allowance 2,743 13,997 Total provision for income taxes $ 25 $ — The provision for income taxes differs from the United States statutory rate as a result of the following (in thousands): At December 31, 2017 December 30, 2016 Tax benefit at U.S. statutory rate $ (15,155 ) $ (13,117 ) State taxes, net of federal benefit (822 ) (1,146 ) Impact of tax reform rate change 11,696 — Other 1,562 266 Valuation allowance – tax reform rate change (11,696 ) — Valuation allowance – other changes 14,440 13,997 Total provision for income taxes $ 25 $ — Deferred tax assets (liabilities) consist of the following (in thousands): Year Ended December 31, 2017 December 30, 2016 Net operating loss carryforwards $ 16,834 $ 10,998 Research and development tax credits 420 — Property, plant and equipment 127 637 Intangible assets 3,281 5,603 Accruals 503 415 Other 861 1,629 Gross deferred tax assets 22,026 19,282 Less valuation allowance (22,026 ) (19,282 ) Net deferred tax assets — — Net deferred tax asset (liability) $ — $ — Deferred income tax assets or liabilities reflect temporary differences between amounts of assets and liabilities, including net operating loss (“ NOL”) carryforwards, for financial and tax reporting. A valuation allowance is provided on deferred tax assets if it is determined that it is more likely than not not On December 22, 2017, and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation reduced the U.S. corporate tax rate from the current maximum rate of 35% 21% December 31, 2017. December 31 2017 34% 2017, 21% $11.7 The Company has approximately $72.2 $29.0 ating losses that could be used to offset taxable income in future periods and reduce its income taxes payable in those future periods. In addition, the Company has approximately $560 not The Company considers all available positive and negative evidence, including the Company ’s current and past performance, the market environment in which the Company operates, the utilization of past tax credits, length of carry back and carry forward periods, existing contracts or sales backlog that will result in future profits, as well as other factors, to determine whether, based on the weight of that evidence, a valuation allowance is needed for some portion or all of a net deferred income tax asset. Judgment is used in considering the relative impact of negative and positive evidence. In arriving at these judgments, the weight given to the potential effect of negative and positive evidence is commensurate with the extent to which such evidence can be objectively verified. In evaluating the objective evidence and the need for a valuation allowance, the Company considered the past three Based on an assessment of the available positive and negative evidence, including the historical operating losses, the Company has concluded that it is more likely than not not As such, the Company has provided a full valuation allowance on the net deferred income tax assets as of December 31, 2017 December 30, 2016. At December 31, 2017, 140 not 740 10 45 10A, no December 31, 2017 December 30, 2016, not A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows (in thousands): December 31, 2017 Balance at beginning of fiscal year $ — Gross amount of increases for current year tax positions 140 Balance at ending of fiscal year $ 140 The Company files annual income tax returns in the United States and various state and local jurisdictions. There are currently no Generally, the Company is no 2014. Pursuant to the terms of the tax matters agreement with Integer, for a period of two ing the date of the spin-off, the Company will be prohibited from (i) causing or permitting to occur any transaction or series of transactions, subject to certain exceptions provided under the U.S. federal income tax rules, in connection with which one 30% 35% March 14, 2018 no

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. COMMITMENTS AND CONTINGENCIES Litigation – not no not On September 19, 2017, tts, against the Company and three No Purchase Commitments – Contractual obligations for purchase of goods or services are defined as agreements that are enforceable and legally binding on the Company and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. The Company’s purchase orders are normally based on its current manufacturing or other operational needs. Inventory to be purchased by Nuvectra in fiscal year 2018 December 31, 2017, no 2018 $2.0 Operating Leases – The Company is a party to various operating lease agreements. See Note 2

Note 10 - Earnings Per Share ("

Note 10 - Earnings Per Share ("EPS")	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	10. EARNINGS PER SHARE (“ EPS”) Basic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is equal to basic net loss per share as the Company had no The following table illustrates the calculation of Ba sic and Diluted EPS (in thousands, except per share amounts): Year Ended December 31, 2017 December 30, 2016 Basic net loss per share: Net loss $ (44,600 ) $ (38,428 ) Weighted average common shares outstanding 10,576 10,277 Basic net loss per share $ (4.22 ) $ (3.74 ) Diluted net loss per share: Net loss $ (44,600 ) $ (38,428 ) Weighted average common shares outstanding 10,576 10,277 Dilutive stock options, restricted stock and restricted stock units — — Weighted average common shares outstanding – assuming dilution 10,576 10,277 Diluted net loss per share $ (4.22 ) $ (3.74 ) Outstanding securities and warrants that were not included in the diluted calculation because their effect would be anti-dilutive 1,402 1,538

Note 11 - Fair Value Measuremen

Note 11 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	11. FAIR VALUE MEASUREMENTS The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these items. As of December 31, 2017, 2 Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). The Company has categorized its warrants measured at fair value on a recurring basis in Level 3 $0.2 2017, $0.6 December 31, 2017 $0.4 The Company ’s investments in marketable securities primarily consist of investments in debt securities, which are classified as available-for-sale and presented as current assets within Cash and Cash Equivalents on the consolidated balance sheet because of their original maturities of three The fair values of marketable securities were estimated using the market approach using prices and other r elevant information generated by market transactions involving identical or comparable assets. The Company uses quoted market prices in active markets or quoted market prices in markets that are not December 31, 2017, $21.3 three Marketable securities, measured at fair value, by level within the fair value hierarchy were as follows (in thousands): December 31, 2017 Fair Value Hierarchy Cost Unrealized Loss Fair Value Cash Level 1 $ 7,336 $ — $ 7,336 Government Level 1 1,499 — 1,499 Financial Level 2 3,799 (1 ) 3,798 Industrial Level 2 8,649 — 8,649 Total $ 21,283 $ (1 ) $ 21,282 December 30, 2016 Fair Value Hierarchy Cost Unrealized Loss Fair Value Cash Level 1 $ 33,821 $ — $ 33,821 Government Level 1 2,005 — 2,005 Financial Level 2 8,064 (1 ) 8,063 Industrial Level 2 11,125 (1 ) 11,124 Total $ 55,015 $ (2 ) $ 55,013 Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. A summary of the valuation methodologies for assets and liabilities measured on a nonrecurring basis is as follows: Long-lived Asse ts – The Company reviews the carrying amount of its long-lived assets to be held and used, other than goodwill, for potential impairment whenever certain indicators are present as described in Note 1 Goodwill – Goodwill recorded is not 1 2017 2016, no Warrants – In order to determine the fair value of the warrants classified as equity awards, the Company used a Monte Carlo simulation model. The risk-free interest rate represents the 10 March 18, 2016. The following table summari zes the assumptions as of December 31, 2017 Risk-free interest rate 2.35 % Expected volatility 70.00 % Contractual term (in years) 10 Dividend yield — %

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	12. STOCKHOLDERS ’ EQUITY The Company is authorized to issue 100 $0.001 one no not March 14, 2016, 10,258,278

Note 13 - Business Segments, Ge

Note 13 - Business Segments, Geographic and Concentration Risk Information	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Segment Reporting, Geographical, and Concentration Risk Disclosure [Text Block]	13. BUSINESS SEGMENTS, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION The Company has two two Nuvectra is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. Algovita is the Company’s first second first NeuroNexus designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Revenues includes sales of neural interface technology, com ponents and systems to the neuroscience and clinical markets. An analysis and reconciliation of the Company ’s product lines, business segments and geographic information to the respective information in the Consolidated Financial Statements follows. Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped or services are rendered (in thousands): Year Ended December 31, 2017 December 30, 2016 Product line sales: Algovita $ 25,567 $ 4,162 Neural interface components and systems 4,756 5,152 Development and engineering service 1,513 3,221 Total sales $ 31,836 $ 12,535 Year Ended December 31, 2017 December 30, 2016 Business segment sales: Nuvectra $ 27,080 $ 7,383 NeuroNexus 4,756 5,152 Total sales $ 31,836 $ 12,535 Year Ended December 31, 2017 December 30, 2016 Segment (loss) income from operations: Nuvectra $ (42,231 ) $ (37,702 ) NeuroNexus 219 300 Total segment loss from operations (42,012 ) (37,402 ) Unallocated operating expenses — — Operating loss (42,012 ) (37,402 ) Unallocated other expense, net (2,563 ) (1,026 ) Loss before provision for income taxes $ (44,575 ) $ (38,428 ) Year Ended December 31, 2017 December 30, 2016 Depreciation and amortization: Nuvectra $ 1,249 $ 1,908 NeuroNexus 366 335 Total depreciation and amortization included in segment income from operations 1,615 2,243 Unallocated depreciation and amortization — — Total depreciation and amortization $ 1,615 $ 2,243 Year Ended December 31, 2017 December 30, 2016 Expenditures for tangible long-lived assets: Nuvectra $ 1,140 $ 3,950 NeuroNexus 91 81 Total reportable segments 1,231 4,031 Unallocated tangible long-lived assets — — Total expenditures $ 1,231 $ 4,031 At December 31, 2017 December 30, 2016 Identifiable assets: Nuvectra $ 83,696 $ 111,503 NeuroNexus 7,407 7,799 Total reportable segments 91,103 119,302 Unallocated assets — — Total assets $ 91,103 $ 119,302 Year Ended December 31, 2017 December 30, 2016 Sales by geographic area: United States $ 26,976 $ 5,800 Non-Domestic locations: Switzerland 1,576 3,461 Germany 1,234 1,567 Rest of world 2,050 1,707 Total sales $ 31,836 $ 12,535 All of the Company ’s long-lived tangible assets are located in the United States.

Note 14 - Related Party Transac

Note 14 - Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	14. RELATED PARTY TRANSACTIONS Corporate Overhead Allocations from Integer – As discussed in Note 1 March 14, 2016, March 14, 2016. not March 14, 2016. $0.2 2016 no 2017. On March 14, 2016 ith Integer to effect the Spin-off and to provide a framework for the Company’s relationship with Integer going forward after the Spin-off including a supply agreement, license agreements, a separation and distribution agreement, a tax matters agreement, a transition services agreement and an employee matters agreement, which provided for the allocation between Nuvectra and Integer of assets, employees, liabilities and obligations (including PP&E, employee benefits, and tax-related assets and liabilities) attributable to the Company’s business for the period prior to, at, and after the Spin-off. Immediately prior to the completion of the Spin-off, Integer made a cash capital contribution to Nuvectra of $75.0 Employee Benefit Plans – Certain of the Company’s employees historically participated in various Integer defined contribution and stock-based compensation plans. Compensation expense allocated to Nuvectra for these plans from Integer was based upon the costs directly attributable to Nuvectra employees. See Note 5 Supply Agreement – The Company has a supply agreement with Integer pursuant to which Integer manufactures Algovita and certain of its components. Total charges incurred under this supply agreement are included in cost of sales. Purchase of Non-controlling Interests – During the fourth 2015, $16.7 $9.9 2015 $6.8 January 1, 2016 January 2016 $6.9 $0.8

Note 15 - Recently Issued Accou

Note 15 - Recently Issued Accounting Standards	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	15. RECENTLY ISSUED ACCOUNTING STANDARDS In the normal course of business, management evaluates all new accounting pronouncements issued by the FASB to determine the potential impact they may not not Recently Adopted In January 2017, ASU”) 2017 04, 350 two not 2017 04 2017 In March 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting,” which amends ASC Topic 718, 2016 09 first 2017 no no no not 2016 09 not In July 2015, 2015 11, Inventory (Topic 330 not first first 2017. 2015 11 not Not In May 2017, ASU 2017 09, 718 2017 09 2017 09, not 2017 09 December 15, 2017. 2017 09 2018. not 2017 09 In January 2017, 2017 01, Business Combinations (Topic 805 2017 01 not not not 2017 01 December 15, 2017, first 2018 not 2017 01 In August 2016, 2016 15, Statement of Cash Flows (Topic 230 2016 15 eight December 15, 2017, first 2018 not 2016 15 In February 2016, 2016 02, Leases” in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. ASU 2016 02 2016 02 December 15, 2018 ( In January 2016, 2016 01, December 15, 2017, first 2018. In May 2014, No. 2014 09, Revenue from Contracts with Customers 606” 606 606 ASC 606, December 15, 2017. On January 1, 2018 606 not The Company has c ompleted an implementation plan to assess the impact of the new guidance on its operations, financial results and related disclosures. To date, we have completed our assessment of the revenue streams and areas of the balance sheet and financial statement components impacted, including assessing the impact of the new guidance on our results of operations and internal controls. The Company ’s revenue streams identified include (i) Algovita US product sales, (ii) Algovita foreign product sales, (iii) NeuroNexus product sales, including those with custom design services and (iv) development and engineering service revenue from the agreement with Aleva Neurotherapeutics, S.A. (“Aleva”). Based on the Company’s analysis of open contracts as of the adoption date, there will be no not one not may not Upon adopting ASC 606, 606 five

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Nature of Operations [Policy Text Block]	Nature of Operations – Nuvectra Corporation, together with its wholly-owned subsidiaries (i) Algostim, LLC (“Algostim”), (ii) PelviStim LLC (“PelviStim”), and (iii) NeuroNexus Technologies, Inc. (“NeuroNexus”) (collectively “Nuvectra” or the “Company”), is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (“SCS”) System (“Algovita”) is the Company’s first
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation – The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions to Form 10 X. On March 14, 2016 Integer”), completed the spin-off of the Company, at which time the Company became a separate public company (the “Spin-off”). Prior to the Spin-off, the Company was a limited liability company named QiG Group, LLC (“QiG”). Prior to March 14, 2016, 2016 Prior to March 14, 2016, ons, including executive oversight, finance, legal, human resources, tax, information technology, product development, corporate procurement, and facilities. These expenses were charged to the Company on the basis of direct usage, when identifiable, with the remainder allocated primarily on a pro rata basis of estimated hours incurred, headcount, square footage, or other measures. The Company’s management considers the expense allocation methodology and results to be reasonable for all periods presented. However, these allocations are not 14 5
Liquidity and Capital Resources [Policy Text Block]	Liquidity and Capital Resources – The Company has incurred significant net losses and negative cash flows from operations since inception and expects to incur additional net losses for the foreseeable future. Immediately prior to completion of the Spin-off, Integer made a cash capital contribution to Nuvectra of $75 $23.8 3,248,750 February 2018, $5 six twelve no may may not may may no
Fiscal Period, Policy [Policy Text Block]	Fiscal Year End – Beginning in fiscal year 2017, 2017, fifty fifty-three December 31. 2016 December 30, 2016 fifty-two
Use of Estimates, Policy [Policy Text Block]	Use of Estimates – The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of sales and expenses during the reporting period. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include inventories, tangible and intangible asset valuations, revenue, stock-based compensation, and income tax accounts.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements – Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e . three Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 1 not Level 2 – Valuation is determined from quoted prices for similar assets or liabilities in active markets, quoted prices for identical instruments in markets that are not Level 3 – Valuation is based on unobservable inputs that are significant to the overall fair value measurement. The degree of judgment in determining fair value is greatest for Level 3 The availability of observable inputs can vary and is affected by a wide variety of factors, including, the type of asset/liability, whether the asset/liability is established in the marketplace, and other characteristics particular to the valuation. To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may Fair value is a market-based measure considered from the persp ective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not 11
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents – Cash and Cash Equivalents consist of cash and highly liquid, short-term investments with maturities at the time of purchase of three
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk – Financial instruments that potentially subject the Company to concentration of credit risk consist principally of trade accounts receivable owed to the Company by its customers. The Company performs on-going credit evaluations of its customers. During fiscal year 2016, $3.1 25% No 10% 2016, no 10% 2017. December 30, 2016 $0.3 No 10% December 30, 2016, no 10% December 31, 2017. may 13
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts – The Company provides credit, in the normal course of business, to its customers in the form of trade accounts receivable. Credit is extended based on evaluation of a customer’s financial condition and collateral is not not $0.4 $0.01 2017 2016,
Inventory, Policy [Policy Text Block]	Inventories – The value of inventories, comprised solely of finished goods, are stated at the lesser of net realizable value or cost, determined using the first first not $0.4 $0.2 2017 2016, may
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Equipment, Net (“ PP&E”) – PP&E is carried at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the assets, as follows: buildings and building improvements 7 40 3 8 3 10 The Company is a party to various operating lease agreements for buildings, machinery, and equipment. Lease expense includes the effect of escalation clauses , which are accounted for ratably over the lease term. Note 2
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Amortizing Intangible Assets, Net – Amortizing Intangible Assets, Net consists primarily of purchased technology and patents, and customer lists. The Company amortizes its definite-lived intangible assets over their estimated useful lives utilizing an accelerated method of amortization, which approximates the projected cash flows used to fair value those intangible assets at the time of acquisition. The amortization period for the Company’s amortizing intangible assets are as follows: purchased technology and patents 6 7 3
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets – The Company assesses the impairment of definite-lived long-lived assets or asset groups when events or changes in circumstances indicate that the carrying value may not not, not 50 Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. The projected cash flows for eac h asset or asset group considers multiple factors, including current revenue from existing customers, proceeds from the sale of the asset or asset group and expected profit margins giving consideration to historical and expected margins. If the carrying value is not no
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill Valuation – The Company assesses its goodwill balances for impairment on the last day of each fiscal year, or more frequently if certain indicators are present or changes in circumstances, as described above, suggest that impairment may first not December 31, 2017 December 30, 2016 not . The following represents our goodwill balance by reportable segment. Changes to goodwill during the years ended December 31, 2017 December 30, 2016 Nuvectra NeuroNexus Total Balance – January 1, 2016 Goodwill, gross $ 33,491 $ 4,691 $ 38,182 Accumulated impairment losses — — — Goodwill, net 33,491 4,691 38,182 Goodwill impairment charge — — — Balance – December 30, 2016 Goodwill, gross 33,491 4,691 38,182 Accumulated impairment losses — — — Goodwill, net 33,491 4,691 38,182 Goodwill impairment charge — — — Balance – December 31, 2017 Goodwill, gross 33,491 4,691 38,182 Accumulated impairment losses — — — Goodwill, net $ 33,491 $ 4,691 $ 38,182
Standard Product Warranty, Policy [Policy Text Block]	Warranty Reserve – The Company offers a warranty on certain of its products and has established a warranty reserve, as a component of other current liabilities, for any potential claims. The Company estimates its warranty reserve based upon an analysis of all identified or expected claims and an estimate of the cost to resolve those claims. Factors that affect the Company’s warranty liability include the number of units sold, historical and anticipated rates of warranty claims, and differences between actual and expected warranty costs per claim. The Company periodically assesses the adequacy of its warranty liabilities and adjusts the amounts as necessary.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition – The Company recognizes revenue when it is realized or realizable and earned. This occurs when persuasive evidence of an arrangement exists, delivery has occurred, the risk of loss is transferred, the price is fixed or determinable, the buyer is obligated to pay (i.e., not no Service revenue is recognized as the services are performed. The Company’s development services are typically provided on a fixed-fee basis. The revenues for such longer duration projects are typically recognized using the proportional performance method. In using the proportional performance method, revenues are generally recorded based on the percentage of effort incurred to date on a contract relative to the estimated total expected contract effort. Estimating total contract effort and progress to completion on the arrangements, as well as whether a loss is expected to be incurred on the contract, requires significant judgment. Management uses historical experience, project plans and an assessment of the risks and uncertainties inherent in the arrangements to establish these estimates. Various uncertainties may may not not
Research and Development Expense, Policy [Policy Text Block]	Research, Development and Engineering Costs, Net (“ RD&E”) – RD&E costs are expensed as incurred. The primary costs are salary and employee benefits for our specialists in software engineering, mechanical engineering, electrical engineering, and graphical user interface design, design verification testing expenses, which include salary and employee benefits for our engineers who test the design and materials used in our medical devices, salary, benefits and other personnel-related expenses for our regulatory, quality and clinical affairs employees, material costs used in development projects and subcontracting costs. Any reimbursements received from government grants are recorded as a reduction of the research, development and engineering costs incurred.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation – three not. The Black-Scholes option-pricing model was used to estimate the fair value of stock options granted. For service-based and nonmarket-base d performance restricted stock unit awards, the fair market value of the award is determined based upon the closing value of the stock price on the grant date. Historically, for market-based performance restricted stock unit awards, the fair market value of the award was determined utilizing a Monte Carlo simulation model, which projected the value of Integer’s stock under numerous scenarios and determined the value of the award based upon the present value of those projected outcomes. The total expense r ecognized over the vesting period will only be for those awards that ultimately vest, excluding market and nonmarket performance award considerations. Note 5
Insurance, Policy [Policy Text Block]	Insurance – The Company historically participated in Integer’s various insurance programs, to insure for property and casualty risks, product liability, employee health care, workers’ compensation and other casualty losses. Many of the potential losses were covered by Integer under conventional insurance programs with third March 14, 2016 no 14
Interest Expense and Income [Policy Text Block]	Interest Expense, Net – Interest expense, including amortization of deferred financing fees and discounts on debt, related to the Company’s Credit Facility was $2.3 $1.4 2017 2016, $0.3 $0.1 2017 2016,
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss – The Company’s comprehensive loss as reported in the Consolidated Statements of Operations and Comprehensive Loss is comprised of the Company’s net loss and unrealized holding period gains and / or losses related to investments.
Income Tax, Policy [Policy Text Block]	Income Taxes – The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not The Company records uncertain tax positions in a ccordance with ASC 740 two 1 not 2 not 50 The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying Consolidated Statement of Operations.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events – The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. On February 5, 2018, public offering of 3,248,750 $8.00 423,750 $26.0 See Note 7 Debt” for additional information on the Company’s credit facility as amended in February 2018.

Note 1 - Summary of Significa23

Note 1 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Goodwill [Table Text Block]	Nuvectra NeuroNexus Total Balance – January 1, 2016 Goodwill, gross $ 33,491 $ 4,691 $ 38,182 Accumulated impairment losses — — — Goodwill, net 33,491 4,691 38,182 Goodwill impairment charge — — — Balance – December 30, 2016 Goodwill, gross 33,491 4,691 38,182 Accumulated impairment losses — — — Goodwill, net 33,491 4,691 38,182 Goodwill impairment charge — — — Balance – December 31, 2017 Goodwill, gross 33,491 4,691 38,182 Accumulated impairment losses — — — Goodwill, net $ 33,491 $ 4,691 $ 38,182

Note 2 - Property, Plant and 24

Note 2 - Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Property, Plant and Equipment [Table Text Block]	At December 31, 2017 December 30, 2016 Machinery and equipment $ 2,329 $ 1,675 Buildings and building improvements 2,855 2,854 Information technology hardware and software 4,431 3,191 Furniture and fixtures 374 314 Land and land improvements 390 390 Construction work in process 342 1,066 Total, gross 10,721 9,490 Accumulated depreciation (4,502 ) (3,173 ) Total, net $ 6,219 $ 6,317
Depreciation and Rent Expense for Property, Plant and Equipment [Table Text Block]	Year Ended December 31, 2017 December 30, 2016 Depreciation expense $ 1,329 $ 1,974 Rent expense 520 519
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2018 $ 445 2019 401 2020 408 2021 415 2022 282 Thereafter — Total estimated operating lease payments $ 1,951

Note 3 - Intangible Assets, N25

Note 3 - Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Gross Carrying Amount Accumulated Amortization Net Carrying Amount At December 30, 2016 Technology and patents $ 1,058 $ (498 ) $ 560 Customer lists 1,869 (715 ) 1,154 Total intangible assets $ 2,927 $ (1,213 ) $ 1,714 At December 31, 2017 Technology and patents $ 1,058 $ (624 ) $ 434 Customer lists 1,869 (875 ) 994 Total intangible assets $ 2,927 $ (1,499 ) $ 1,428
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Year Ended December 31, 2017 December 30, 2016 Cost of sales $ 126 $ 110 Selling, general and administrative expenses 160 159 Total intangible asset amortization expense $ 286 $ 269
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated Amortization Expense 2018 $ 298 2019 293 2020 209 2021 194 2022 108 Thereafter 326 Total estimated amortization expense $ 1,428

Note 4 - Accrued Liabilities (T

Note 4 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	At December 31, 2017 December 30, 2016 Inventory purchases $ 5,825 $ 547 Regulatory, clinical and quality 358 640 Legal 358 98 Deferred revenue 335 — Sales and marketing 321 108 Operations engagement fee 200 600 Interest 199 99 Warranty reserve 195 98 Research and development 164 165 Sales and use tax 145 56 Insurance 127 — Information technology system implementations 114 327 Travel and entertainment — 285 Accrued other 486 332 Total accrued liabilities $ 8,827 $ 3,355

Note 5 - Employee Benefit Pla27

Note 5 - Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	Year Ended December 31, 2017 December 30, 2016 Stock options $ 864 $ 638 Restricted stock and restricted stock units 1,451 1,732 Total stock-based compensation expense $ 2,315 $ 2,370 Year Ended December 31, 2017 December 30, 2016 Selling, general and administrative expense $ 1,992 $ 1,565 Research, development and engineering costs, net 323 336 Other operating expenses — 469 Total stock-based compensation expense $ 2,315 $ 2,370
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2017 December 30, 2016 Weighted average fair value $ 3.64 $ 4.52 Risk-free interest rate 2.06 % 1.72 % Expected volatility 55 % 55 % Holding period (in years) 6 10 Expected dividend yield — % — %
Restricted Stock and RSU's [Member]
Notes Tables
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Time-Vested Activity Weighted Average Fair Value Nonvested at December 30, 2016 551,224 $ 6.90 Granted 209,218 6.76 Vested (229,667 ) 8.76 Forfeited (101,770 ) 6.52 Nonvested at December 31, 2017 429,005 $ 6.88
Employee Stock Option [Member]
Notes Tables
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Number of Time-Vested Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding at December 30, 2016 873,992 $ 6.49 Granted 338,839 6.84 Exercised (261,748 ) 5.80 Forfeited or expired (80,263 ) 7.18 Outstanding at December 31, 2017 870,820 $ 6.78 7.59 $ 1,203,654 Exercisable at December 31, 2017 423,547 $ 6.53 6.18 $ 736,883

Note 7 - Debt (Tables)

Note 7 - Debt (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	At December 31, 2017 December 30, 2016 Term loan $ 29,631 $ 16,163 Deferred financing fees (962 ) (1,262 ) Discount on debt (1,994 ) (1,157 ) Total debt 26,675 13,744 Less current portion of long-term debt 789 — Total long-term debt $ 25,886 $ 13,744
Schedule of Debt Issuance Costs [Table Text Block]	At January 1, 2016 $ — Additions during the period 1,528 Amortization during the period (266 ) At December 30, 2016 $ 1,262 At December 30, 2016 $ 1,262 Additions during the period 47 Amortization during the period (347 ) At December 31, 2017 $ 962

Note 8 - Income Taxes (Tables)

Note 8 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended December 31, 2017 December 30, 2016 Current tax expense $ 25 $ — Deferred tax benefit (2,743 ) (13,997 ) Change in valuation allowance 2,743 13,997 Total provision for income taxes $ 25 $ —
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	At December 31, 2017 December 30, 2016 Tax benefit at U.S. statutory rate $ (15,155 ) $ (13,117 ) State taxes, net of federal benefit (822 ) (1,146 ) Impact of tax reform rate change 11,696 — Other 1,562 266 Valuation allowance – tax reform rate change (11,696 ) — Valuation allowance – other changes 14,440 13,997 Total provision for income taxes $ 25 $ —
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Year Ended December 31, 2017 December 30, 2016 Net operating loss carryforwards $ 16,834 $ 10,998 Research and development tax credits 420 — Property, plant and equipment 127 637 Intangible assets 3,281 5,603 Accruals 503 415 Other 861 1,629 Gross deferred tax assets 22,026 19,282 Less valuation allowance (22,026 ) (19,282 ) Net deferred tax assets — — Net deferred tax asset (liability) $ — $ —
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	December 31, 2017 Balance at beginning of fiscal year $ — Gross amount of increases for current year tax positions 140 Balance at ending of fiscal year $ 140

Note 10 - Earnings Per Share 30

Note 10 - Earnings Per Share ("EPS") (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, 2017 December 30, 2016 Basic net loss per share: Net loss $ (44,600 ) $ (38,428 ) Weighted average common shares outstanding 10,576 10,277 Basic net loss per share $ (4.22 ) $ (3.74 ) Diluted net loss per share: Net loss $ (44,600 ) $ (38,428 ) Weighted average common shares outstanding 10,576 10,277 Dilutive stock options, restricted stock and restricted stock units — — Weighted average common shares outstanding – assuming dilution 10,576 10,277 Diluted net loss per share $ (4.22 ) $ (3.74 ) Outstanding securities and warrants that were not included in the diluted calculation because their effect would be anti-dilutive 1,402 1,538

Note 11 - Fair Value Measurem31

Note 11 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	December 31, 2017 Fair Value Hierarchy Cost Unrealized Loss Fair Value Cash Level 1 $ 7,336 $ — $ 7,336 Government Level 1 1,499 — 1,499 Financial Level 2 3,799 (1 ) 3,798 Industrial Level 2 8,649 — 8,649 Total $ 21,283 $ (1 ) $ 21,282 December 30, 2016 Fair Value Hierarchy Cost Unrealized Loss Fair Value Cash Level 1 $ 33,821 $ — $ 33,821 Government Level 1 2,005 — 2,005 Financial Level 2 8,064 (1 ) 8,063 Industrial Level 2 11,125 (1 ) 11,124 Total $ 55,015 $ (2 ) $ 55,013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	Risk-free interest rate 2.35 % Expected volatility 70.00 % Contractual term (in years) 10 Dividend yield — %

Note 13 - Business Segments, 32

Note 13 - Business Segments, Geographic and Concentration Risk Information (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Revenue from External Customers by Products and Services [Table Text Block]	Year Ended December 31, 2017 December 30, 2016 Product line sales: Algovita $ 25,567 $ 4,162 Neural interface components and systems 4,756 5,152 Development and engineering service 1,513 3,221 Total sales $ 31,836 $ 12,535
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year Ended December 31, 2017 December 30, 2016 Business segment sales: Nuvectra $ 27,080 $ 7,383 NeuroNexus 4,756 5,152 Total sales $ 31,836 $ 12,535 Year Ended December 31, 2017 December 30, 2016 Segment (loss) income from operations: Nuvectra $ (42,231 ) $ (37,702 ) NeuroNexus 219 300 Total segment loss from operations (42,012 ) (37,402 ) Unallocated operating expenses — — Operating loss (42,012 ) (37,402 ) Unallocated other expense, net (2,563 ) (1,026 ) Loss before provision for income taxes $ (44,575 ) $ (38,428 ) Year Ended December 31, 2017 December 30, 2016 Depreciation and amortization: Nuvectra $ 1,249 $ 1,908 NeuroNexus 366 335 Total depreciation and amortization included in segment income from operations 1,615 2,243 Unallocated depreciation and amortization — — Total depreciation and amortization $ 1,615 $ 2,243 Year Ended December 31, 2017 December 30, 2016 Expenditures for tangible long-lived assets: Nuvectra $ 1,140 $ 3,950 NeuroNexus 91 81 Total reportable segments 1,231 4,031 Unallocated tangible long-lived assets — — Total expenditures $ 1,231 $ 4,031 At December 31, 2017 December 30, 2016 Identifiable assets: Nuvectra $ 83,696 $ 111,503 NeuroNexus 7,407 7,799 Total reportable segments 91,103 119,302 Unallocated assets — — Total assets $ 91,103 $ 119,302
Revenue from External Customers by Geographic Areas [Table Text Block]	Year Ended December 31, 2017 December 30, 2016 Sales by geographic area: United States $ 26,976 $ 5,800 Non-Domestic locations: Switzerland 1,576 3,461 Germany 1,234 1,567 Rest of world 2,050 1,707 Total sales $ 31,836 $ 12,535

Note 1 - Summary of Significa33

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Feb. 05, 2018	Mar. 14, 2016	Feb. 28, 2018	Dec. 31, 2017	Dec. 30, 2016
Proceeds from Contributions from Former Parent					$ 86,421
Line of Credit, Portion Subject to Certain Revenue Milestones		$ 5,000
Revenue, Net				31,836	12,535
Allowance for Doubtful Accounts Receivable, Current				417	10
Inventory Write-down				417	156
Interest Expense				2,300	1,400
Investment Income, Interest				$ 300	$ 100
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				261,748	50,794
Integer Equity Incentives Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				3 years
Patented Technology [Member]
Finite-Lived Intangible Asset, Useful Life				6 years
Customer Lists [Member]
Finite-Lived Intangible Asset, Useful Life				7 years
Building and Building Improvements [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life				7 years
Building and Building Improvements [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life				40 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life				3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life				8 years
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life				3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life				10 years
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Aleva Neurotherapeutics S.A. [Member]
Revenue, Net					$ 3,100
Concentration Risk, Percentage					25.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Aleva Neurotherapeutics S.A. [Member]
Accounts Receivable, Net					$ 300
Underwritten Follow-on Public Offering [Member] | Subsequent Event [Member]
Proceeds from Issuance of Common Stock			$ 23,800
Stock Issued During Period, Shares, New Issues	3,248,750		3,248,750
Sale of Stock, Price Per Share	$ 8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	423,750
Proceeds from Issuance of Common Stock and Exercise of Options, Gross	$ 26,000
Integer [Member]
Proceeds from Contributions from Former Parent		$ 75,000
Period in Which Contribution from Parent Will Fund Operations		1 year

Note 1 - Summary of Significa34

Note 1 - Summary of Significant Accounting Policies - Changes to Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016	Jan. 01, 2016
Goodwill, gross	$ 38,182	$ 38,182	$ 38,182
Accumulated impairment losses
Goodwill, net	38,182	38,182	38,182
Goodwill impairment charge	0	0
Nuvectra Segment [Member]
Goodwill, gross	33,491	33,491	33,491
Accumulated impairment losses
Goodwill, net	33,491	33,491	33,491
Goodwill impairment charge
NeuroNexus Segment [Member]
Goodwill, gross	4,691	4,691	4,691
Accumulated impairment losses
Goodwill, net	4,691	4,691	$ 4,691
Goodwill impairment charge

Note 2 - Property, Plant and 35

Note 2 - Property, Plant and Equipment, Net - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 30, 2016
Property, Plant and Equipment, Gross	$ 10,721	$ 9,490
Accumulated depreciation	(4,502)	(3,173)
Total, net	6,219	6,317
Machinery and Equipment [Member]
Property, Plant and Equipment, Gross	2,329	1,675
Building and Building Improvements [Member]
Property, Plant and Equipment, Gross	2,855	2,854
Information Technology Hardware and Software [Member]
Property, Plant and Equipment, Gross	4,431	3,191
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross	374	314
Land and Land Improvements [Member]
Property, Plant and Equipment, Gross	390	390
Construction in Progress [Member]
Property, Plant and Equipment, Gross	$ 342	$ 1,066

Note 2 - Property, Plant and 36

Note 2 - Property, Plant and Equipment, Net - Depreciation and Rent Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016
Depreciation expense	$ 1,329	$ 1,974
Rent expense	$ 520	$ 519

Note 2 - Property, Plant and 37

Note 2 - Property, Plant and Equipment, Net - Minimum Future Estimated Annual Operating Lease Expenses (Details) $ in Thousands	Dec. 31, 2017USD ($)
2,018	$ 445
2,019	401
2,020	408
2,021	415
2,022	282
Thereafter
Total estimated operating lease payments	$ 1,951

Note 3 - Intangible Assets, N38

Note 3 - Intangible Assets, Net - Amortizing Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 30, 2016
Gross carrying amount	$ 2,927	$ 2,927
Accumulated amortization	(1,499)	(1,213)
Net carrying amount	1,428	1,714
Patented Technology [Member]
Gross carrying amount	1,058	1,058
Accumulated amortization	(624)	(498)
Net carrying amount	434	560
Customer Lists [Member]
Gross carrying amount	1,869	1,869
Accumulated amortization	(875)	(715)
Net carrying amount	$ 994	$ 1,154

Note 3 - Intangible Assets, N39

Note 3 - Intangible Assets, Net - Aggregate Intangible Asset Amortization Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016
Intangible asset amortization expense	$ 286	$ 269
Cost of Sales [Member]
Intangible asset amortization expense	126	110
Selling, General and Administrative Expenses [Member]
Intangible asset amortization expense	$ 160	$ 159

Note 3 - Intangible Assets, N40

Note 3 - Intangible Assets, Net - Future Intangible Asset Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 30, 2016
2,018	$ 298
2,019	293
2,020	209
2,021	194
2,022	108
Thereafter	326
Total estimated amortization expense	$ 1,428	$ 1,714

Note 4 - Accrued Liabilities -

Note 4 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 30, 2016
Inventory purchases	$ 5,825	$ 547
Regulatory, clinical and quality	358	640
Legal	358	98
Deferred revenue	335
Sales and marketing	321	108
Operations engagement fee	200	600
Interest	199	99
Warranty reserve	195	98
Research and development	164	165
Sales and use tax	145	56
Insurance	127
Information technology system implementations	114	327
Travel and entertainment		285
Accrued other	486	332
Total accrued liabilities	$ 8,827	$ 3,355

Note 5 - Employee Benefit Pla42

Note 5 - Employee Benefit Plans (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Apr. 01, 2016	Dec. 31, 2017	Dec. 30, 2016
Proceeds From Stock Options and Warrants Exercised		$ 1,430	$ 249
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		261,748	50,794
Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Exercises in Period		32,425
Proceeds from Stock Options Exercised			$ 200
401K Plan [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match		25.00%	25.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent		6.00%	6.00%
Defined Contribution Plan, Cost		$ 300	$ 200
Integer Sponsored, 401K Plan [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	35.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	6.00%
Defined Contribution Plan, Cost			200
Bonus Plan [Member]
Deferred Compensation Arrangement with Individual, Compensation Expense		$ 1,900	1,000
Nuvectra Corporation 2016 Equity Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance		1,541,195
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost		$ 2,300	$ 1,300
Nuvectra Corporation 2016 Equity Incentive Plan [Member] | Restricted Stock Units and Non-Qualified Stock Options [Member] | Directors, Certain Officers and Key Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options and Options, Grants in Period		548,057	805,222
Integer Equity Incentives Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost		$ 200	$ 1,100
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 3,300
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		1 year 219 days

Note 5 - Employee Benefit Pla43

Note 5 - Employee Benefit Plans - Allocated Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016
Allocated share-based compensation expense	$ 2,315	$ 2,370
Selling, General and Administrative Expenses [Member]
Allocated share-based compensation expense	1,992	1,565
Research and Development Expense [Member]
Allocated share-based compensation expense	323	336
Other Operating Income (Expense) [Member]
Allocated share-based compensation expense		469
Employee Stock Option [Member]
Allocated share-based compensation expense	864	638
Restricted Stock and RSU's [Member]
Allocated share-based compensation expense	$ 1,451	$ 1,732

Note 5 - Employee Benefit Pla44

Note 5 - Employee Benefit Plans - Weighted Average Fair Value Assumption Used to Values Options Granted (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016
Weighted average fair value (in dollars per share)	$ 3.64	$ 4.52
Risk-free interest rate	2.06%	1.72%
Expected volatility	55.00%	55.00%
Holding period (in years) (Year)	6 years	10 years
Expected dividend yield	0.00%	0.00%

Note 5 - Employee Benefit Pla45

Note 5 - Employee Benefit Plans - Summary of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016
Exercised, number of options (in shares)	(261,748)	(50,794)
Employee Stock Option [Member]
Outstanding, number of options (in shares)	873,992
Outstanding, weighted average exercise price (in dollars per share)	$ 6.49
Granted, number of options (in shares)	338,839
Granted, weighted average exercise price (in dollars per share)	$ 6.84
Exercised, number of options (in shares)	(261,748)
Exercised, weighted average exercise price (in dollars per share)	$ 5.80
Forfeited or expired, number of options (in shares)	(80,263)
Forfeited or expired, weighted average exercise price (in dollars per share)	$ 7.18
Outstanding, number of options (in shares)	870,820	873,992
Outstanding, weighted average exercise price (in dollars per share)	$ 6.78	$ 6.49
Outstanding, weighted average remaining contractual life (Year)	7 years 215 days
Outstanding, aggregate intrinsic value	$ 1,203,654
Exercisable, number of options (in shares)	423,547
Exercisable, weighted average exercise price (in dollars per share)	$ 6.53
Exercisable, weighted average remaining contractual life (Year)	6 years 65 days
Exercisable, aggregate intrinsic value	$ 736,883

Note 5 - Employee Benefit Pla46

Note 5 - Employee Benefit Plans - Summary Restricted Stock Unit Activity (Details) - Restricted Stock and RSU's [Member]	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Nonvested (in shares) | shares	551,224
Nonvested (in dollars per share) | $ / shares	$ 6.90
Granted (in shares) | shares	209,218
Granted (in dollars per share) | $ / shares	$ 6.76
Vested (in shares) | shares	(229,667)
Vested (in dollars per share) | $ / shares	$ 8.76
Forfeited (in shares) | shares	(101,770)
Forfeited (in dollars per share) | $ / shares	$ 6.52
Nonvested (in shares) | shares	429,005
Nonvested (in dollars per share) | $ / shares	$ 6.88

Note 6 - Other Operating Expe47

Note 6 - Other Operating Expenses (Details Textual)	Mar. 14, 2016USD ($)
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost	$ 469,000

Note 7 - Debt (Details Textual)

Note 7 - Debt (Details Textual) - USD ($)	Feb. 28, 2018	Feb. 16, 2018	Sep. 28, 2017	Mar. 18, 2016	Dec. 31, 2017	Dec. 30, 2016	Feb. 14, 2017
Payments of Debt Issuance Costs					$ 47,000	$ 1,528,000
Proceeds from Issuance of Long-term Debt					12,500,000	$ 15,000,000
Derivative Liability				$ 200,000	400,000
Warrants in Connection with Term Loan A [Member] | Additional Paid-in Capital [Member]
Warrants and Rights Outstanding				$ 200,000
Warrants in Connection with Term Loan B [Member] | Additional Paid-in Capital [Member]
Warrants and Rights Outstanding			$ 400,000
Warrants in Connection with Term Loan C [Member]
Class of Warrant or Right, Increase to Warrant, Percentage of Loan Divided by Market Value of Common Stock				4.50%
Warrants in Connection with Term Loan C [Member] | Other Noncurrent Liabilities [Member]
Derivative Liability					400,000
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member] | Piper Jaffray [Member]
Payments of Debt Issuance Costs				$ 1,125,000
Debt Instrument, Arrangement Fee, Percentage				2.50%
Oxford Finance LLC and Silicon Valley Bank [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 5,000,000
Line of Credit Facility, Commitment Fee Amount				$ 25,000
Oxford Finance LLC [Member]
Class of Warrant or Right, Issued During Period			22,844
Class of Warrant or Right, Issued During Period, Exercise Price			$ 12.31
Oxford Finance LLC [Member] | Warrants in Connection with Term Loan A [Member]
Class of Warrant or Right, Issued During Period				56,533
Class of Warrant or Right, Issued During Period, Exercise Price				$ 5.97
Oxford Finance LLC [Member] | Subsequent Event [Member]
Class of Warrant or Right, Issued During Period	30,245
Class of Warrant or Right, Issued During Period, Exercise Price	$ 9.30
Silicon Valley Bank [Member] | Warrants in Connection with Term Loan B [Member]
Class of Warrant or Right, Issued During Period			22,844	56,533
Class of Warrant or Right, Issued During Period, Exercise Price			$ 12.31	$ 5.97
Silicon Valley Bank [Member] | Subsequent Event [Member]
Class of Warrant or Right, Issued During Period	30,245
Class of Warrant or Right, Issued During Period, Exercise Price	$ 9.30
Term Loans [Member] | Oxford Finance LLC and Silicon Valley Bank [Member]
Debt Agreement, Maximum Borrowing Capacity				$ 40,000,000	$ 45,000,000
Debt Instrument, Interest Rate Floor					8.65%
Debt Instrument, Interest Rate During Period					8.40%
Debt Instrument, Percentage of Funded Loan Amounts due at Maturity					7.75%
Debt Instrument, Commitment Fee Amount				$ 200,000
Debt Instrument, Amendment Fee							$ 25,000
Term Loans [Member] | Oxford Finance LLC and Silicon Valley Bank [Member] | Subsequent Event [Member]
Loan Amendment Payment		$ 800,000
Term Loans [Member] | Oxford Finance LLC and Silicon Valley Bank [Member] | If Term Loan B Funded, Beginning April, 2018 [Member]
Debt Instrument, Number of Monthly Principal and Interest Payments					30
Term Loans [Member] | Oxford Finance LLC and Silicon Valley Bank [Member] | Prepayment in First Year After Initial Closing [Member]
Debt Instrument, Prepayment Fee Percentage					3.00%
Term Loans [Member] | Oxford Finance LLC and Silicon Valley Bank [Member] | Prepayment in Second Year After Initial Closing [Member]
Debt Instrument, Prepayment Fee Percentage					2.00%
Term Loans [Member] | Oxford Finance LLC and Silicon Valley Bank [Member] | Prepayment After Second Year After Initial Closing [Member]
Debt Instrument, Prepayment Fee Percentage					1.00%
Term Loans [Member] | Oxford Finance LLC and Silicon Valley Bank [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate					4.15%
Term Loan A [Member] | Oxford Finance LLC and Silicon Valley Bank [Member]
Debt Agreement, Maximum Borrowing Capacity					$ 27,500,000
Term Loan A [Member] | Oxford Finance LLC and Silicon Valley Bank [Member] | Subsequent Event [Member]
Proceeds from Issuance of Long-term Debt		27,500,000
Term Loan B [Member] | Oxford Finance LLC and Silicon Valley Bank [Member]
Debt Agreement, Maximum Borrowing Capacity					$ 12,500,000
Term Loan B [Member] | Oxford Finance LLC and Silicon Valley Bank [Member] | Subsequent Event [Member]
Proceeds from Issuance of Long-term Debt		$ 12,500,000
Term Loan C [Member]
Debt Covenant, Maximum Number of Days to Draw Loan After Revenue Requirement					60 days
Debt Instrument, Commitment Fee Percentage					5.00%
Term Loan C [Member] | Oxford Finance LLC and Silicon Valley Bank [Member]
Debt Agreement, Maximum Borrowing Capacity					$ 5,000,000
Debt Covenant, Minimum Product Revenue Required for Trailing Six Months					$ 25,000,000

Note 7 - Debt - Long-term Debt

Note 7 - Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 30, 2016
Term loan	$ 29,631	$ 16,163
Deferred financing fees	(962)	(1,262)
Discount on debt	(1,994)	(1,157)
Total debt	26,675	13,744
Less current portion of long-term debt	789
Total long-term debt	$ 25,886	$ 13,744

Note 7 - Debt - Deferred Financ

Note 7 - Debt - Deferred Financing Fees (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016
Deferred financing fees	$ 1,262
Additions during the period	47	1,528
Amortization during the period	(347)	(266)
Deferred financing fees	$ 962	$ 1,262

Note 8 - Income Taxes (Details

Note 8 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Mar. 14, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 30, 2016
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			34.00%
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Deferred True-up, Amount			$ 11,696
Unrecognized Tax Benefits			140
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued			$ 0	$ 0
Greatbatch [Member]
Tax Matters Agreement, Term	2 years
Greatbatch [Member] | Tax Matters Agreement [Member]
Equity Issuance Limitations			30.00%
Asset Disposal Limitations			35.00%
Domestic Tax Authority [Member]
Operating Loss Carryforwards			$ 72,200
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount			560
State and Local Jurisdiction [Member]
Operating Loss Carryforwards			$ 29,000
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		21.00%

Note 8 - Income Taxes - Provisi

Note 8 - Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016
Current tax expense	$ 25
Deferred tax benefit	(2,743)	(13,997)
Change in valuation allowance	2,743	13,997
Provision for income taxes	$ 25

Note 8 - Income Taxes - Tax Rat

Note 8 - Income Taxes - Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016
Tax benefit at U.S. statutory rate	$ (15,155)	$ (13,117)
State taxes, net of federal benefit	(822)	(1,146)
Impact of tax reform rate change	11,696
Other	1,562	266
Valuation allowance – tax reform rate change	(11,696)
Valuation allowance – other changes	14,440	13,997
Total provision for income taxes	$ 25

Note 8 - Income Taxes - Deferre

Note 8 - Income Taxes - Deferred Tax Assets (Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 30, 2016
Deferred tax assets, net operating loss carryforwards	$ 16,834	$ 10,998
Deferred tax assets, research & development tax credits	420
Deferred tax assets, property, plant & equipment	127	637
Deferred tax assets, intangible assets	3,281	5,603
Accruals	503	415
Deferred tax assets, other	861	1,629
Deferred tax assets, gross deferred tax assets	22,026	19,282
Less valuation allowance	(22,026)	(19,282)
Net deferred tax assets
Net deferred tax asset (liability)

Note 8 - Income Taxes - Unrecog

Note 8 - Income Taxes - Unrecognized Tax Benefits (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Balance at beginning of fiscal year
Gross amount of increases for current year tax positions	140
Balance at ending of fiscal year	$ 140

Note 9 - Commitments and Cont56

Note 9 - Commitments and Contingencies (Details Textual) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)
Capital Expenditures Yet to Be Incurred	$ 2

Note 10 - Earnings Per Share 57

Note 10 - Earnings Per Share ("EPS") (Details Textual) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016
Weighted Average Number Diluted Shares Outstanding Adjustment	0	0

Note 10 - Earnings Per Share 58

Note 10 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016
Basic net loss per share:
Net loss	$ (44,600)	$ (38,428)
Weighted average common shares outstanding (in shares)	10,576	10,277
Basic net loss per share (in dollars per share)	$ (4.22)	$ (3.74)
Diluted net loss per share:
Net loss	$ (44,600)	$ (38,428)
Weighted average common shares outstanding (in shares)	10,576	10,277
Dilutive stock options, restricted stock and restricted stock units (in shares)
Weighted average common shares outstanding – assuming dilution (in shares)	10,576	10,277
Diluted net loss per share (in dollars per share)	$ (4.22)	$ (3.74)
Warrant [Member]
Diluted net loss per share:
Outstanding securities and warrants that were not included in the diluted calculation because their effect would be anti-dilutive (in shares)	1,402	1,538

Note 11 - Fair Value Measurem59

Note 11 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016	Mar. 18, 2016
Derivative Liability	$ 400		$ 200
Fair Value Adjustment of Warrants	600
Available-for-sale Securities	21,282	$ 55,013
Goodwill, Impairment Loss	$ 0	$ 0

Note 11 - Fair Value Measurem60

Note 11 - Fair Value Measurements - Marketable Securities Measured at Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 30, 2016
Available-for-sale Securities, Amortized Cost Basis	$ 21,283	$ 55,015
Available-for-sale Securities, Accumulated Gross Unrealized Loss	(1)	(2)
Available-for-sale Securities	21,282	55,013
Cash [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Amortized Cost Basis	7,336	33,821
Available-for-sale Securities, Accumulated Gross Unrealized Loss
Available-for-sale Securities	7,336	33,821
US Treasury and Government [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Amortized Cost Basis	1,499	2,005
Available-for-sale Securities, Accumulated Gross Unrealized Loss
Available-for-sale Securities	1,499	2,005
Financial Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Amortized Cost Basis	3,799	8,064
Available-for-sale Securities, Accumulated Gross Unrealized Loss	(1)	(1)
Available-for-sale Securities	3,798	8,063
Industrial Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Amortized Cost Basis	8,649	11,125
Available-for-sale Securities, Accumulated Gross Unrealized Loss		(1)
Available-for-sale Securities	$ 8,649	$ 11,124

Note 11 - Fair Value Measurem61

Note 11 - Fair Value Measurements - Fair Value Assumptions of Warrants (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2017
Risk-free interest rate	2.35%
Expected volatility	70.00%
Contractual term (in years) (Year)	10 years
Dividend yield	0.00%

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity (Details Textual) - $ / shares	Dec. 31, 2017	Dec. 30, 2016	Mar. 14, 2016
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares, Outstanding	10,849,385	10,319,627	10,258,278

Note 13 - Business Segments, 63

Note 13 - Business Segments, Geographic and Concentration Risk Information (Details Textual)	12 Months Ended
	Dec. 31, 2017
Number of Reportable Segments	2
Number of Reporting Units	2

Note 13 - Business Segments, 64

Note 13 - Business Segments, Geographic and Concentration Risk Information - Product Line Sales (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016
Revenue, Net	$ 31,836	$ 12,535
Algovita [Member]
Revenue, Net	25,567	4,162
Neural Interface Components and Systems [Member]
Revenue, Net	4,756	5,152
Development and Engineering Services [Member]
Revenue, Net	$ 1,513	$ 3,221

Note 13 - Business Segments, 65

Note 13 - Business Segments, Geographic and Concentration Risk Information - Business Segments Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016
Revenue, Net	$ 31,836	$ 12,535
Segment loss from operations	(42,012)	(37,402)
Unallocated operating expenses	57,962	43,507
Unallocated other expense, net	(2,563)	(1,026)
Loss before provision for income taxes	(44,575)	(38,428)
Depreciation and amortization	1,615	2,243
Expenditures for tangible long-lived assets	1,231	4,031
Identifiable assets	91,103	119,302
Operating Segments [Member]
Segment loss from operations	(42,012)	(37,402)
Depreciation and amortization	1,615	2,243
Expenditures for tangible long-lived assets	1,231	4,031
Identifiable assets	91,103	119,302
Segment Reconciling Items [Member]
Unallocated operating expenses
Depreciation and amortization
Expenditures for tangible long-lived assets
Identifiable assets
Nuvectra Segment [Member]
Revenue, Net	27,080	7,383
Nuvectra Segment [Member] | Operating Segments [Member]
Segment loss from operations	(42,231)	(37,702)
Depreciation and amortization	1,249	1,908
Expenditures for tangible long-lived assets	1,140	3,950
Identifiable assets	83,696	111,503
NeuroNexus Segment [Member]
Revenue, Net	4,756	5,152
NeuroNexus Segment [Member] | Operating Segments [Member]
Segment loss from operations	219	300
Depreciation and amortization	366	335
Expenditures for tangible long-lived assets	91	81
Identifiable assets	$ 7,407	$ 7,799

Note 13 - Business Segments, 66

Note 13 - Business Segments, Geographic and Concentration Risk Information - Sales by Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 30, 2016
Revenue, Net	$ 31,836	$ 12,535
UNITED STATES
Revenue, Net	26,976	5,800
SWITZERLAND
Revenue, Net	1,576	3,461
GERMANY
Revenue, Net	1,234	1,567
Rest of World [Member]
Revenue, Net	$ 2,050	$ 1,707

Note 14 - Related Party Trans67

Note 14 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands	Mar. 14, 2016	Jan. 31, 2016	Jan. 01, 2016	Jan. 31, 2016	Dec. 31, 2017	Dec. 30, 2016
Noncontrolling Interest, Increase from Business Combination			$ 16,700
Payments to Noncontrolling Interests		$ 6,800	$ 9,900			$ 6,818
Integer [Member]
Proceeds from Contributions from Parent	$ 75,000
Drees Holding LLC [Member]
Payments to Noncontrolling Interests				$ 6,900
Executive Vice President of Research and Development [Member]
Payments to Noncontrolling Interests				$ 800
Selling, General and Administrative Expenses [Member] | Integer [Member]
Corporate Overhead Allocation					$ 0	$ 200